Announcements
- Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2024
- Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 30 avril 2024
- PHAXIAM Therapeutics annonce le recrutement du premier patient dans l’étude de phase 1 dans l’endocardite infectieuse causée par le Staphylococcus aureus
- PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus
- Monthly information related to total number of voting rights and shares composing the share capital – March 29, 2024
- Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 mars 2024
- PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)
- PHAXIAM Therapeutics annonce le dépôt de son Document d’Enregistrement Universel (URD) 2023
- PHAXIAM Announces 2023 Full-Year Results and Provides Business Update
- PHAXIAM Therapeutics publie ses résultats annuels 2023 et fait le point sur ses activités
More ▼
Key statistics
On Friday, Phaxiam Therapeutics SA (2E40:FRA) closed at 2.78, 0.91% above its 52-week low of 2.75, set on Mar 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.87 |
---|---|
High | 2.87 |
Low | 2.78 |
Bid | 2.78 |
Offer | 3.03 |
Previous close | 2.86 |
Average volume | 0.00 |
---|---|
Shares outstanding | 6.08m |
Free float | 5.60m |
P/E (TTM) | -- |
Market cap | 17.47m EUR |
EPS (TTM) | -5.56 EUR |
Data delayed at least 15 minutes, as of May 03 2024 20:49 BST.
More ▼